CRISPR Therapeutics (CRSP) Tops Q2 EPS by 115c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q2 EPS of ($0.98), $1.15 better than the analyst estimate of ($2.13). Revenue for the quarter came in at $70 thousand versus the consensus estimate of $1.8 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
• BMO Capital Reiterates Outperform Rating on CMS Energy (CMS)